title: A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms.
abstract: The inhibitory effects of magnetic fields (MFs) on tumor cell proliferation in vitro and in vivo have been reported in previous studies. However, the effects of MFs in the treatment of cancer have not been described in clinical trials. We investigated the effects of 420 r/min, 0.4-T extremely low-frequency MFs (ELF-MFs) on the survival and palliation of general symptoms in 13 advanced non-small cell lung cancer (NSCLC) patients. Toxicity and side-effects were assessed according to WHO criteria. The treatment area included the primary tumor site, metastatic sites and metastatic lymph nodes. Additionally, the patients were treated 2 h per day, 5 days per week for 6-10 weeks. The changes in general symptoms were analyzed during ELF-MF treatment and 2 weeks after the completion of therapy. Results of physical examination, routine analysis of blood, ECG and liver function, biochemical and kidney function tests were evaluated before and following treatment. All 13 patients were followed up by outpatient service or telephone interview. Our results demonstrated that decreased pleural effusion, remission of shortness of breath, relief of cancer pain, increased appetite, improved physical strength, regular bowel movement and better sleep quality was detected in 2 (15.4%), 5 (38.5%), 5 (38.5%), 6 (46.2%), 9 (69.2%), 1 (7.7%) and 2 (15.4%) patients, respectively. However, the palliation of symptoms in 2 (15.4%) patients was observed during therapy and disappeared at treatment termination. No severe toxicity or side-effects were detected in our trial. The median survival was 6.0 months (95% CI, 1.0-11.0). The 1- and 2-year survival rates were 31.7 and 15.9%, respectively. This study is the first to describe survival and palliation of general symptoms in advanced NSCLC patients treated with ELF-MFs. As an effective, well-tolerated and safe treatment choice, ELF-MFs may prolong survival and improve general symptoms of advanced NSCLC patients. However, this treatment strategy requires further research.
authors.affiliation: Department of Tumor Research and Therapy Center, Provincial Hospital Affiliated to Shandong University, Shandong University, Shandong 250021,  P.R. China.
authors.forename: Chengtao
authors.initials: C
authors.lastname: Sun
authors.forename: Huiming
authors.initials: H
authors.lastname: Yu
authors.forename: Xingwen
authors.initials: X
authors.lastname: Wang
authors.forename: Junqing
authors.initials: J
authors.lastname: Han